


Lannebo Sverige Plus

Swedish-registered equity fund
Monthly report August 2020


The money you invest in a fund can both increase and decrease in value and it is not certain that you will get back the full amount invested.

| | | | | | | | | | | | |
|----------|----------|----------|----------|----------|----------|----------|-----------------|----------|----------|----------|----------|
| Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 |
|----------|----------|----------|----------|----------|----------|----------|-----------------|----------|----------|----------|----------|

Monthly performance



Performance YTD



Martin Wallin and Robin Nestor

Performance

| | Lannebo Sverige Plus | Benchmark |
|---------------------------------|----------------------|-----------|
| Performance, % | | |
| August 2020 | 5.5 | 3.7 |
| Year-to-date 2020 | 2.6 | 3.5 |
| 3 years | 29.5 | 37.2 |
| 5 years | 58.6 | 62.9 |
| 10 years | 223.5 | 209.2 |
| Since launch (12/11/08) | 477.8 | 406.5 |
| Average annual return 24 months | 5.6 | 9.6 |
| 2019 ¹ | 22.6 | 35.0 |
| 2018 ¹ | -0.7 | -4.4 |
| 2017 ¹ | 8.8 | 9.5 |
| 2016 ¹ | 13.3 | 9.6 |
| 2015 ¹ | 13.4 | 10.5 |

¹ The performance is based on closing prices.

Closed production chains led to narrowed product ranges

Veoneer in forward-looking collaboration with Qualcomm.

The risk appetite remains high on the Stockholm Stock Exchange, which defies global uncertainties brought on by covid-19. Macro indicators in the form of global PMI and industrial production have improved each month and are beginning to reach levels from the previous year. A recovery in the form of a so-called "v-shaped curve" has taken place at a much faster pace than we, and many others, expected. Recently, most of the companies we have listened to and talked with express an underlying optimism regarding order intake and production volumes.

The spread of the coronavirus remains high in some geographies, while the growth in Scandinavia has slowed down significantly. Development of a vaccine continues and there are great hopes of a full-fledged vaccine during 2021. Covid-19, with its spread, has also revealed societal weaknesses. It is fairly certain that pandemics will ravage the world again - but no one knows when and in what form. This time it was a virus that spread from person to person, next time it might be between computers.

Monthly performance, %

| Jan | Feb | Mar | Apr | May | Jun |
|-----|------|-------|------|-----|-----|
| 0.9 | -8.5 | -17.5 | 14.8 | 4.8 | 1.0 |
| Jul | Aug | Sep | Oct | Nov | Dec |
| 5.0 | 5.5 | | | | |


Veoneer and Autoliv developed positively during the month, increasing 38 and 19 per cent, respectively. Both companies have been under pressure during the Spring as a result of sharply reduced production of passenger cars. Subcontractors are now witnessing an improvement - from underproduction to increasing production volumes and stock replenishments. Veoneer, which is facing an eventful Autumn with several production starts, announced at the end of August that the company had entered into a partnership with American Qualcomm. The collaboration means that the two companies will develop a software and hardware product platform for the next generation of advanced driver support for cars. Veoneer will be responsible for software development and, thanks to Qualcomm, the company will have a broader customer base and product portfolio.

Autoliv has managed the difficult Spring well - falling sales, sharply reduced order intake and short lead times for production-adjustments have been partly managed through flexibility and cost reductions. After the company's sales fell by 65 and 55 per cent in April and May, respectively, data for July passenger cars sales reveal a rapid global return to similar levels as in 2019. Recovered demand and low inventories at dealers explain the pent-up demand.

Securitas and AstraZeneca developed weaker than the market as a whole with share price declines during the month of 6 and 2 per cent, respectively. Securitas' Q2 earnings report was good and in accordance with our expectations. Profitability held up well and the operating margin, before depreciation, decreased by one percentage point to 4 per cent. Reduced revenue from, for example, airports have been offset in other sectors, particularly for the business area North America. Free cash flow for the quarter amounted to just over SEK 2 billion and was a clear improvement over the same period last year, even when excluding the positive effects from reduced VAT and social security contributions.

AstraZeneca, which is collaborating with Oxford University on a covid-19 vaccine, reported a positive result for a Phase 1 study. The small number of participants in the study developed an immune response, while no serious side effects were noted. AstraZeneca, which committed to sell the vaccine at cost during the pandemic's continuance, has now signed delivery agreements with most countries and regions around the world. If the upcoming evaluation studies are positive, the vaccine is expected to be available for delivery at the beginning of next year.

Sector allocation



| # | Sector | % of the fund |
|----|------------------------|---------------|
| 1. | Industrials | 31.3 |
| 2. | Financials | 18.5 |
| 3. | Consumer discretionary | 20.5 |
| 4. | Information technology | 12.2 |
| 5. | Health care | 9.3 |
| 6. | Materials | 4.2 |
| 7. | Real estate | 1.3 |
| 8. | Communication services | 0.2 |
| | Cash | 2.5 |

10 largest holdings

| Holding | % of the fund |
|----------------------------------|---------------|
| Nokia EUR | 5.7 |
| Ericsson B | 5.6 |
| Nordea | 5.6 |
| SKF B | 5.5 |
| H&M B | 5.3 |
| SEB A | 5.2 |
| Trelleborg B | 5.0 |
| Volvo B | 4.7 |
| Swedbank A | 4.6 |
| Electrolux B | 4.3 |
| Total 10 largest holdings | 51.4 |
| Cash | 2.5 |
| Total number of holdings | 35 |

Major changes during the month

Buy

Sandvik
Stora Enso
AstraZeneca

Sell

Investor
ABB
Husqvarna

Risk and reward profile

| | | | | | | | | |
|------------|---|---|---|---|---|---|-------------|--|
| Lower risk | | | | | | | Higher risk | |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | | |

Financial ratios

| | Lannebo Sverige Plus | Benchmark |
|-------------------------------------|----------------------|-----------|
| Sharpe ratio | 0.4 | 0.6 |
| Total risk (%) | 23.0 | 19.0 |
| Tracking error | 7.2 | |
| Information ratio | -0.5 | |
| Alpha | -0.4 | |
| Beta | 1.2 | |
| Active share | 67 | |
| Gross equity exposure (%) | 99 | |
| Net equity exposure (%) | 98 | |
| Portfolio turnover ratio (06/30/20) | 1.7 | |

Fund facts

| | |
|---------------------------|---|
| Fund manager | Martin Wallin & Robin Nestor |
| Launch date | 12/11/08 |
| NAV per unit (SEK) | 56.33 |
| Fund size (SEKm) | 3,978 |
| Management fee | 1.0% + 20% of any excess return |
| Return threshold | SIX Portfolio Return Index |
| Bankgiro | 346-3585 |
| ISIN | SE0002686584 |
| Trading frequency | Daily |
| Minimum investment amount | SEK 100 |
| PPM number | 490 292 |
| Supervisory authority | Finansinspektionen |
| LEI | 549300W8FUNESQQE9448 |

Risk information

Past returns are no guarantee of future returns. The money invested in the fund may increase or decrease in value and it is not certain that you will get back all the capital you have invested. The key investor information document and prospectus can be found at lannebo.se/en. Please note that Lannebo does not produce investment recommendations or other information recommending or suggesting an investment strategy. Information in this monthly report should not be seen as anything other than a statement of the fund's trading activities and holdings

The fund is suitable for those who

- Want a Swedish equity fund with greater opportunities.
- Want an actively managed fund with investments based on a clear understanding of each individual.

The fund's investment policy

Lannebo Sverige Plus is an actively managed equity fund that primarily invests in shares on the Swedish equity market. The fund is similar to a traditional equity fund, but with more flexible investment rules. The "Plus" label reflects the fund's ability to invest more than 100 per cent of the fund's assets. For example, the fund can invest 130 per cent in shares that the fund managers are positive about and balance this by reducing its equity exposure by 30 per cent through the sale of shares that the fund does not own. i.e. short selling.

Explanations

Benchmark SIX Portfolio Return Index. The unit price of the fund is set before the price of the index is calculated. This can sometimes result in a misleading comparison between the two.

Sharpe ratio Sharpe ratio is a measure of risk adjusted return. Calculated as the ratio of the fund's excess return above the risk-free rate of return and the fund's total risk.

Total risk Given as the standard deviation of variations in the total return of the fund or index.

Tracking error Tracking error is a measure of active risk in a fund. Calculated as the standard deviation of the difference between the return of the fund and its benchmark.

Information ratio A measure of risk-adjusted return. This is measured as the active return divided by the portfolio's active risk.

Alpha Describes the effect of the portfolio manager's decisions on the return of the fund. A positive alpha value is the risk-adjusted excess return relative to the return of the benchmark.

Beta Beta is a measure of a fund's sensitivity to market movements. The beta value reports how much the fund's value changes in percentage terms when the market's value changes by one percentage point.

Active share A measure of the proportion of the portfolio that differ from the benchmark.

All financial ratios are calculated according to guidelines of the Swedish Investment Fund Association.

